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Summary
Low-dose alemtuzumab has shown a favourable toxicity profile coupled with
good results in terms of efficacy in relapsed/refractory chronic lymphocytic
leukaemia (CLL). We conducted a multicentre retrospective study on the
routine clinical use of low-dose alemtuzumab in this patient setting. One
hundred and eight relapsed/refractory CLL patients from 11 Italian centres
were included in the analysis. All patients had an Eastern Cooperative
Oncology Group performance status £2 and the majority (84%) had
adenopathies <5cm. Low-dose alemtuzumab was defined as a total weekly
dose £45 mg and a cumulative dose £600 mg given for up to 18 weeks. The
overall response rate was 56% (22% complete remissions). After a median
follow-up of 42Æ2 months, the median overall survival and progression-free
survival were 39Æ0 and 19Æ4 months, respectively. In univariate analysis,
response was inversely associated with lymph node (P = 0Æ01) and spleen
(P = 0Æ02) size, fludarabine-refractoriness (P = 0Æ01) and del(11q)
(P = 0Æ009). Advanced age and del(17p) were not associated with a worse
outcome. Cumulative dose of alemtuzumab was not associated to response.
Toxicities were usually mild and manageable; severe infections occurred in
seven patients (7%) during therapy. This retrospective analysis confirms that
low-dose alemtuzumab is a valid and currently used therapeutic option for
the treatment of relapsed/refractory CLL.
Keywords: alemtuzumab, chronic lymphocytic leukaemia, infection, mono-
clonal antibodies.
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Introduction
Alemtuzumab (Campath-1H), is an IgG1 kappa monoclonal
antibody specific for the cell surface glycoprotein CD52
expressed on normal and malignant B and T lymphocytes
(Gribben & Hallek, 2009; Hallek & Pflug, 2011). Over the last
decade, alemtuzumab as single agent has been utilized in
chronic lymphocytic leukaemia (CLL) as first-line treatment
(Osterborg et al, 1996; Lundin et al, 2002; Hillmen et al, 2007)
and in relapsed/refractory patients (Osterborg et al, 1997;
Keating et al, 2002; Rai et al, 2002; Stilgenbauer & Dohner,
2002; Lozanski et al, 2004; Stilgenbauer et al, 2009). Results
have been encouraging, because the antibody has shown
activity even when the commonly used fludarabine-based
chemoimmunotherapy strategies have failed, at least in
patients without bulky disease (Keating et al, 2002; Rai et al,
2002; Lozanski et al, 2004; Stilgenbauer et al, 2009). Moreover,
alemtuzumab appears to be active on CLL cells in a p53
independent manner, thus being an effective therapy for
patients carrying del(17p) or mutations of the TP53 gene, that
are commonly resistant to conventional treatments (Stil-
genbauer & Dohner, 2002; Lozanski et al, 2004; Zenz et al,
2009).
However, the major obstacle to the widespread use of
alemtuzumab outside clinical trials is that treatment is
associated with profound immunosuppression leading to a
high rate of severe infections (Keating et al, 2002; Nosari et al,
2004; Stilgenbauer et al, 2009). The expected rate of severe
complications associated with alemtuzumab therapy has
hampered the use of this monoclonal antibody in patients
categorized as frail by clinicians (Nosari et al, 2004, 2008;
Morrison, 2010).
It has been previously shown that alemtuzumab, given at a
lower dose, is a safe and effective treatment in CLL (Cortelezzi
et al, 2005, 2009; Laurenti et al, 2005; Bezares et al, 2011; Gritti
et al, 2011). Alemtuzumab was administered at a weekly dose
that was one-third (30 vs. 90 mg) and a cumulative dose that
was half (540 vs. 1080 mg) of those commonly employed
(Cortelezzi et al, 2005, 2009; Gritti et al, 2011), with a
prolonged treatment course (18 vs. 12 weeks). The safety
results of these studies have shown that severe infections
occurred in about 8% of patients without deaths during
treatment; this incidence appears lower than those reported
when alemtuzumab is administered at conventional doses
(Keating et al, 2002; Cortelezzi et al, 2009; Stilgenbauer et al,
2009; Gritti et al, 2011).
The perception that alemtuzumab may be administered in a
safer way using lower doses came into clinical practice in
several Italian haematological institutions far before the
definitive results of the abovementioned trials were available.
In the present retrospective study, we have therefore evaluated
the routine clinical use of low-dose alemtuzumab in 11 Italian
haematological centres.
Patients and methods
Patients
Adult (‡18 years) CLL patients treated with low-dose ale-
mtuzumab outside clinical trials were included in this retro-
spective study. All the participating centres adopted the policy
to use alemtuzumab at low dose. Alemtuzumab was defined at
low-dose if the total weekly dose was £45 mg and the
cumulative dose was £600 mg. Duration of treatment was
accepted up to 18 weeks of therapy; both subcutaneous (SC)
and intravenous (IV) administrations were allowed. Other
inclusion criteria were diagnosis of CLL requiring treatment
according to the 1996 National Cancer Institute-sponsored
Working Group (NCIWG) guidelines (Cheson et al, 1996) and
at least one previous therapy not containing alemtuzumab as
single agent or in combination.
The study was conducted in accordance with the Declara-
tion of Helsinki, approved by the Ethic Committee and
registered at the regulatory bureau (Agenzia Italiana del
Farmaco) in accordance with Italian law.
Assessment
A set of clinical variables were documented at baseline,
including previous treatments, age, sex, lymph node size,
presence of hepato-splenomegaly, spleen size evaluated by
imaging, Binet stage and haematological parameters. A series
of biological prognostic markers were collected, including the
analysis of genomic aberrations by interphase fluorescence
in situ hybridization (FISH) for del(17p13), del(11q22),
trisomy 12 and del(13q14); IGHV mutation status by sequenc-
ing; CD38 and ZAP70 expression. Positivity for CD38 and
ZAP70 was defined according to local laboratory practice.
Treatment schedule, planned and given doses were assessed.
Response was defined according to the NCIWG criteria
(Cheson et al, 1996). Infusion-related toxicities and infections
were documented and reported according to the NCI CTCAE
v3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/docs/ctcaev3.pdf). Haematological toxicity was
assessed by means of the NCIWG guidelines (Cheson et al, 1996).
Statistical considerations
Differences in the distributions of prognostic factors in
subgroups were analysed by chi-square or the Fisher’s exact
test, and by the Kruskal–Wallis test. The probability of overall
survival (OS) and progression-free survival (PFS) was esti-
mated using the Kaplan–Meier method. The log-rank test was
used to compare treatment effect and risk factor categories,
while 95% confidence intervals (95% CIs) were estimated
using the Simon and Lee method. Logistic regression and Cox
proportional hazard regression models were performed to
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examine risk factors affecting treatment response [responders:
complete remission (CR), partial remission (PR); non-
responders: stable disease (SD), progressive disease (PD)]
and survival outcomes. All tests were two-sided, accepting
P £ 0Æ05 as indicating a statistically significant difference. All
statistical analyses were performed with the statistical software
environment R (R Development Core Team, 2009).
Results
Patients characteristics
One hundred and eight CLL patients, treated between March
2002 and December 2009 at 11 Italian centres, were included in
the analysis. The baseline patient characteristics are summa-
rized in Table I. Median age was 68 years (range 43–85) and 45
patients (42%) were older than 70 years. The majority of
patients had advanced disease; almost half of them were Binet
stage C (n = 50, 46%). Seventeen patients (16%) presented
with bulky lymph nodes (‡5 cm) and 59 (55%) had a palpable
splenomegaly. Performance status (PS) according to the
Eastern Cooperative Oncology Group (ECOG) was 0–1 in 94
patients (87%) and two in 14 patients (13%). No patient
presented with a poorer performance status. Patients with an
ECOG PS of two were characterized by advanced disease (79%
Binet stage C), bulky adenopathies (36%) and fludarabine
refractoriness (79%). The median number of previous lines of
therapy was two (range 1–6). Most patients were treated with
chlorambucil (n = 81, 75%); 36 (33%) patients were treated
with single-agent fludarabine, 35 were exposed to rituximab-
based chemoimmunotherapy (32%) and 36 (33%) were
treated with fludarabine in combination with cyclophospha-
mide, with or without rituximab. Refractoriness to alkylating
agents and fludarabine-containing regimens was documented
in 59 (55%) and 48 (44%) patients, respectively.
The biological risk profile was available only for some of the
cohort (see Table I). A high proportion of patients showed an
unfavourable profile: 44% were positive for del(17p) or
del(11q) at FISH analysis; an unmutated IGHV profile was
detected in 67% of cases; CD38 and ZAP70 positivity was
present in 51% and 60% of cases, respectively.
Schedule
Four schedules of low-dose alemtuzumab were reported. Fifty-
five patients (51%) received 10 mg of alemtuzumab infusion
three times weekly; the planned treatment duration was
10 weeks in 17 patients, 12 weeks in three and 18 weeks in
35 patients. A second cohort of 37 patients (34%) started
therapy according to the previously described schedule and,
when the lymphocyte count was reduced by 1 log, they were
put on a weekly infusion of 30 mg up to 18 weeks of therapy.
Eleven patients (10%) received 30 mg of alemtuzumab once
weekly for 12 weeks (n = 6) or 18 weeks (n = 5). In the
remaining five cases (5%), 15 mg of alemtuzumab was
administered thrice weekly for 12 weeks. In 14 cases (13%),
alemtuzumab was administered by intravenous (IV) infusion,
while the remaining patients were treated subcutaneously (SC).
Three patients were concomitantly treated with oral dexa-
methasone at a dose of 0Æ75–1 mg/d.
Table I. Baseline demographic and clinical characteristics.
Number of
patients (%) or
median (range)
Age (years) 68 (43–85)
‡70 45 (42)
‡65 72 (67)
Sex
Male 73 (68)
Female 35 (32)
Binet stage
A 20 (19)
B 38 (35)
C 50 (46)
Time since initial diagnosis (years) 4Æ9 (0Æ7–23Æ0)
Prior lines of therapy 2 (1–6)
Previous treatment
Chlorambucil 81 (75)
Fludarabine single agent 36 (33)
Rituximab + chemotherapy 35 (32)
(R)-FC 36 (33)
Autotransplant 2 (2)
Alkylating agents refractory 59 (55)
Fludarabine refractory 48 (44)
Maximum lymph node size (cm) 2Æ5 (0Æ5–13Æ5)
‡5 cm 17 (16)
Palpable hepatomegaly 43 (40)
Palpable splenomegaly 59 (55)
Spleen size in cm, evaluated by imaging (n = 85) 14 (9–25)
>12 cm 58 (68)
ECOG PS
0–1 94 (87)
2 14 (13)
White blood cell count (· 109/l) 54Æ9 (2Æ1–288)
Haemoglobin concentration (g/l) 119 (60–151)
Platelet count (· 106/l) 47 (9–272)
Hierarchical FISH subgroups (n = 97)
del(17p) 25 (26)
del(11q) 18 (19)
Trisomy 12 (no 11q- or 17p-) 8 (8)
Normal 33 (34)
Isolated del(13q) 17 (18)
IGHV mutation status (n = 49)
Mutated 16 (33)
Unmutated 33 (67)
CD38 expression (n = 92) 47 (51)
ZAP70 expression (n = 80) 48 (60)
(R)-FC, fludarabine (F) plus cyclophosphamide (C) with or without
rituximab (R); ECOG PS, Eastern Cooperative Oncology Group per-
formance status; FISH, fluorescence in situ hybridization.
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Treatment was completed in 60 patients (55%), and 14
additional patients received more than 75% of the planned
therapy. Only 17 patients (16%) received <50% of the planned
treatment, four of whom (4%) stopped treatment before
completing the fourth week of therapy.
Efficacy
Response Most patients (n = 97, 90%) were assessed by means
of imaging (computerized tomography scan or echography)
and/or bone marrow examination. Only one patient was
merely evaluated clinically; the remaining 10 patients showed
disease progression during treatment.
The overall response rate (ORR) was 56%, with 24 patients
(22%) achieving CR; stabilization and progression of disease
were observed in 24 (22%) and 24 patients (22%), respectively
(Table II). The univariate analysis for response is detailed in
Table SI. Response rates in elderly patients (‡70 years) were
not significantly different compared to those of younger
patients [Odds Ratio (OR): 1Æ4, 95% CI: 0Æ6–2Æ9, P = 0Æ43].
There was an inverse association between lymph node size and
response (P = 0Æ01); in particular, patients with bulky lymph
nodes (‡5 cm) had an ORR of 29%, significantly lower
compared to the 60% recorded in patients presenting without
significant adenopathies (OR: 3Æ7, 95% CI: 1Æ2–11Æ4, P = 0Æ01).
Similarly, spleen size negatively influenced response (OR: 0Æ9,
95% CI: 0Æ78–0Æ98, P = 0Æ02). When patients were stratified
according to Binet stage, a trend towards a lower response with
stage progression was observed, although this result was not
significant (P = 0Æ07). None of the 14 patients with an ECOG
PS of 2 responded to treatment (P < 0Æ0001).
There was an inverse correlation between the number of
previous treatment lines and response (P = 0Æ0098). Patients
with a fludarabine-refractory disease showed significantly
poorer responses compared to the others (OR: 4Æ4, 95% CI:
1Æ3–14Æ5, P = 0Æ01).
Patients carrying del(11q) showed a poor response (OR: 4Æ5,
95% CCI: 1Æ5–13Æ9, P = 0Æ0061); this adverse outcome
remained significant in the multivariate analysis that included
the presence of bulky lymph nodes (P = 0Æ0348). The analysis
of the other biological prognostic factors did not highlight any
difference in response rates. In particular, patients carrying
del(17p) showed a similar ORR compared to the other patients
(OR: 0Æ8, 95% CCI: 0Æ3–2Æ1, P = 0Æ68).
Finally, no relationship between dose of alemtuzumab and
response was observed both in the full cohort of patients and
in the subgroups analysed (P = 0Æ39). Similarly, the schedule
of administration did not appear to influence the response
rates (P = 0Æ31).
Multivariate analysis for response was performed, including
previous treatment with fludarabine, lines of treatment, age,
white blood cell count, spleen size, bulky lymph nodes and
del(11q). Spleen size (OR: 0Æ9, 95% CCI: 0Æ77–0Æ99, P= 0Æ03) and
presence of del(11q) (OR: 5Æ5, 95% CCI: 1Æ3–22Æ7, P = 0Æ02),
were identified as independent negative factors while presence of
lymph nodes ‡5 cm (OR: 3Æ8, 95% CCI: 1Æ0–14Æ9, P = 0Æ06)
showed a non-significant trend toward lower response.
Overall survival and progression-free survival After a median
follow-up of 42Æ2 months (range 2Æ1–91Æ9), 55 deaths were
recorded, 44 of which were related to CLL (disease
progression, associated with lethal infections in most cases).
Table II. Responses by clinical and biological characteristics.
n
ORR
no. (%)
CR
no. (%)
PR
no. (%)
SD
no. (%)
PD
no. (%) P
All 108 60 (56) 24 (22) 36 (34) 24 (22) 24 (22)
FISH 17p- 25 15 (60) 6 (24) 9 (36) 8 (32) 2 (8) 0Æ68
11q- 18 5 (28) 4 (22) 1 (6) 8 (44) 5 (28) 0Æ0061
Other 58 37 (64) 15 (26) 22 (38) 7 (12) 14 (24)
Age (years) <70 63 37 (59) 15 (24) 22 (35) 12 (19) 14 (22) 0Æ43
5 ‡70 45 23 (51) 9 (20) 14 (31) 12 (27) 10 (22)
Binet stage A 20 14 (70) 5 (25) 9 (45) 4 (20) 2 (10) 0Æ07
B 38 24 (63) 11 (29) 13 (34) 6 (16) 8 (21)
C 50 22 (44) 8 (16) 14 (28) 14 (28) 14 (28)
Maximum lymph
node size (cm)
<5 81 49 (60) 21 (26) 28 (35) 17 (21) 15 (19) 0Æ01
‡5 17 5 (29) 2 (12) 3 (18) 5 (29) 7 (41)
ECOG PS <2 94 60 (64) 24 (26) 36 (38) 17 (18) 17 (18) <0Æ0001
=2 14 0 (0) 0 (0) 0 (0) 7 (50) 7 (50)
Previous treatment Fludarabine-
refractory
48 17 (35) 3 (6) 14 (29) 12 (25) 19 (40) 0Æ01
Other 60 43 (72) 21 (35) 22 (37) 12 (20) 5 (8)
FISH, fluorescence in situ hybridization; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate; CR,
complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
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Causes of death unrelated to CLL included seven patients with
second tumours and one patient deceased after a major
trauma. In three cases, it was not possible to document the
cause of death.
Median OS and PFS were 39Æ0 months (95% CI: 29Æ8–58Æ4)
and 19Æ4 months (95% CI: 15Æ9–23Æ5), respectively (Fig 1A, B).
Variables associated with a shorter OS were presence of bulky
lymph nodes [29Æ8 months (95% CI: 13Æ6–33Æ4) vs.
45Æ1 months (95% CI: 32Æ6–64Æ1), P = 0Æ017, Fig 2A] and
fludarabine-refractoriness [26Æ5 months (95% CI: 18Æ5–33Æ1)
vs. not reached (95% CI: 33Æ0 – not reached), P = 0Æ003,
Fig 2C]. PFS was significantly reduced in patients with bulky
lymph nodes [13Æ6 months (95% CI: 3Æ9–19Æ0) vs. 21Æ2 months
(95% CI: 16Æ6–28Æ7), P = 0Æ01, Fig 2B] and in fludarabine-
refractory patients [12Æ5 months (95% CI: 9Æ2–17Æ3) vs. 20Æ0
(95% CI: 14Æ0 – not reached), P = 0Æ004, Fig 2D].
Del(11q) and/or del (17p) did not influence patient survival
(Fig 1C). In particular, in patients carrying del(17p) showed
no difference in OS (Fig 1C) and PFS (Fig 1D) compared to
the other patients.
Advanced age (‡70 years) did not influence PFS (Fig S1A),
while a significantly reduced OS was observed (P = 0Æ03,
supplementary Fig 1A). Despite influencing treatment re-
sponse, spleen size did not show any significant effect on OS
and PFS (P = 0Æ47). Similarly, the treatment schedule did not
influence patient outcome (P = 0Æ91, data not shown).
Safety
Alemtuzumab was well tolerated and no deaths were observed
during therapy. A summary of adverse events (AEs) is shown
in Table III. Injection-related events included fever (with or
without chills and rigours) and injection site reactions, which
occurred in 39% and 55% of the patients treated with SC
alemtuzumab, respectively; the majority of events were mild
(grade 1–2) and severe injection reactions and fever occurred
in 3 (3%) and 2 (2%) patients, respectively. Grade 1–2 fever
complicated the infusion of 6 patients (43%) treated with
alemtuzumab IV; no severe infusion-related event was however
reported.
Haematological toxicities were frequent, but usually mild;
grade 3–4 neutropenia, thrombocytopenia and anaemia
occurred in 29%, 6% and 6% of patients, respectively.
Primary prophylaxis with acyclovir or analogues was
performed in all patients. Weekly cytomegalovirus (CMV)
reactivation surveillance by means of early pp65 CMV
antigenaemia or by CMV DNA quantification was carried
out in all patients. CMV reactivation occurred in 38 patients
(35%) and was managed with temporary treatment interrup-
tion. There was only one case of CMV disease, which resolved
after treatment with intravenous ganciclovir.
Non-CMV infections were documented in 37 patients
(34%). However, severe (grade 3–4) infections occurred only
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Fig 1. (A) Overall survival and (B) progression-free survival of the full patient series (n = 108). (C) Overall survival and (D) progression-free survival
according to cytogenetic subgroup; red line: del(17p) (n = 25), black line: del(11q) (n = 18), green line: other (n = 58).
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in seven patients (7%) with no difference between responders
(n = 4) and non-responders (n = 3); they included bacterial
pneumonia (n = 3), soft-tissue infection (n = 2), sepsis
(n = 1) and fever of unknown origin (n = 1).
Serology for hepatitis B virus (HBV) was available in 83
patients (Table IV). Five patients started therapy with active
HBV infection, defined by the presence of hepatitis B surface
antigen and/or plasmatic HBV-DNA, and nine patients had a
serological profile of occult infection, defined by the presence
of antibodies to the hepatitis B core antigen. In these patients,
treatment with lamivudine was started. Only one patient with
occult HBV infection developed a viral reactivation that was
controlled by the addition of adefovir to lamivudine. No
hepatic adverse events were reported in this cohort of
patients.
Of the 85 patients assessed, seven were positive for hepatitis
C virus (HCV) serology and HCV-RNA documented an active
infection in three cases. Patients were treated without the
occurrence of significant adverse events; in one case, ale-
mtuzumab administration was temporarily interrupted due to
a significant increase of HCV-RNA associated with grade 1
alteration of liver enzymes.
Discussion
The present retrospective study evaluated the routine clinical
use of low-dose alemtuzumab in 11 Italian haematological
centres. The main purpose was to assess the efficacy and safety
of this treatment approach in the ‘real world’ population,
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Fig 2. (A) Overall survival and (B) progression-free survival according to lymph node size; red line: lymph nodes ‡5 cm (n = 17), black line: lymph
nodes <5 cm (n = 81). (C) Overall survival and (D) progression-free survival according to response to fludarabine; red line: fludarabine refractory
(n = 48), black line: fludarabine sensitive or not exposed (n = 60).
Table III. Adverse events using the National Cancer Institute Toxicity
Grades.
Patients experiencing adverse event (n = 108)
no. (%)
All Grade Grade 1–2 Grade 3–4
Infusion related (SC only, n = 94)
Injection site reaction 52 (55) 49 (52) 3 (3)
Fever 34 (36) 32 (34) 2 (2)
Haematological
Anaemia 53 (49) 47 (44) 6 (6)
Neutropenia 64 (62) 34 (33) 30 (29)
Thrombocytopenia 41 (38) 35 (33) 6 (6)
Infections
CMV events 38 (35) 37 (34) 1 (1)
Non-CMV infections 37 (34) 30 (28) 7 (7)
SC, subcutaneously; CMV, cytomegalovirus.
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where therapies investigated in clinical trials are actually used
(Gribben, 2010; Danese et al, 2011). By means of a similar
approach, an Austrian retrospective study confirmed the
activity of standard dose alemtuzumab in an unselected cohort
of pretreated CLL patients in the routine clinical practice
setting (Fiegl et al, 2006, 2010); however, the reported severe
infection rate was 37%, confirming the toxicity of this
treatment when given at full dose (Fiegl et al, 2006).
Demographic data of the 108 patients analysed in the
present study show that low-dose alemtuzumab was preferen-
tially used to treat older patients. In addition, the majority of
the patient population was highly pretreated and in many cases
patients also carried adverse clinical and biological prognostic
factors. Specifically, there was a high prevalence of del(17p)
and nearly half of the patients were treatment-refractory. The
baseline assessment revealed that patients typically presented
with progressive lymphocytosis and/or marrow insufficiency,
with only a minor proportion of patients showing bulky lymph
nodes or spleen. The decision to use alemtuzumab at lower
doses appears to be the net result of the will to offer an effective
treatment and the consideration of the frailty of the patients, in
terms of age, comorbidities and previous exposure to highly
toxic regimens.
All patients were treated according to a defined low-dose
alemtuzumab schedule (i.e. total weekly dose £45 mg, cumu-
lative dose £600 mg, treatment duration £18 weeks) and most
of them completed the planned treatment. Despite this,
patients were treated quite heterogeneously and none of the
applied schedules appeared superior; however, due to the
variability of alemtuzumab schedule and the retrospective
nature of the study, it is not possible to draw definitive
conclusions. In this regard, we suggest that schedules validated
in Phase II trials should be used (Cortelezzi et al, 2009; Gritti
et al, 2011).
The concomitant use of alemtuzumab and corticosteroids
provided interesting results in high risk CLL and became part of
the common practice in many institutions (Pettitt et al, 2006).
Only three patients received a continuous dose of corticosteroids
during low-dose alemtuzumab therapy, showing that this
concomitant treatment is not common practice in Italy.
It can, however, be concluded that low-dose alemtuzumab
appears to be a safe and effective treatment not only within
clinical trials (Cortelezzi et al, 2005, 2009; Laurenti et al, 2005;
Bezares et al, 2011; Gritti et al, 2011), but also in the routine
clinical practice. Data from the present study and from
previously published Phase II trials appear to be comparable in
terms of efficacy to alemtuzumab given at conventional doses
(Keating et al, 2002; Rai et al, 2002; Stilgenbauer & Dohner,
2002; Fiegl et al, 2006, 2010; Stilgenbauer et al, 2009). This
favourable therapeutic effect is associated with an apparently
better toxicity profile.
The main criticism of retrospective studies is that the
interpretation of the data may be biassed by patient selection.
In this regard, we believe that our cohort of patients is
representative of the true population of patients treated with
low-dose alemtuzumab in common practice. All the partici-
pating centres in this study adopted the policy to treat patients
only with low-dose alemtuzumab due to safety concerns with
the standard dose; therefore, there was no selection of standard
versus low dose alemtuzumab. Additionally, the fairly low rate
of early treatment interruption in our series (4%) is in line
with previously published results of prospective trials (Cort-
elezzi et al, 2009; Gritti et al, 2011).
The only selection of patients in the study was relative to its
clinical practice based nature. In fact, alemtuzumab is generally
used on the base of previously published results clearly
showing that the drug is almost ineffective or too toxic in
patients with bulky disease and/or poor performance status
(Keating et al, 2004; Osterborg et al, 2009). Accordingly, in
our cohort there was a limited presence of patients with bulky
adenopathies, significantly enlarged spleen and poor perfor-
mance status that may not be representative of a highly
pretreated and high risk CLL population. This selection should
however not be considered a bias as it mirrors the common use
of alemtuzumab in the clinical practice.
Treatment with alemtuzumab abolished the adverse effect of
several prognostic factors; in particular, patients carrying del
(17p) showed similar response rates with a non-significant
trend towards a lower OS. Interestingly, the presence of
del(11q) affected the response rates independently of other
associated variables, particularly the presence of bulky lymph
nodes, but this effect did not translate into differences in PFS
or OS. The only variables associated with poor prognosis in
terms of OS were treatment refractoriness (fludarabine-
refractory) and/or the presence of bulky disease. While the
first group of patients still benefited, at least in part, from
alemtuzumab therapy (Keating et al, 2002; Stilgenbauer et al,
2009), an effective treatment of refractory patients with bulky
disease is still lacking. Patients with ECOG PS two included in
our study were characterized by both bulky disease and
refractoriness to fludarabine and the prognosis was accordingly
poor.
The toxicity of low-dose alemtuzumab was limited, con-
firming the good tolerability of treatment outside clinical trials
(Cortelezzi et al, 2009; Gritti et al, 2011). In particular, the low
rate of infections makes this treatment strategy suitable for frail
and elderly patients.
Table IV. Hepatits B and C virus during alemtuzumab.
no. %
Hepatitis B virus (HBV) 83 100
HBV-exposed 14 17
Active (HBsAg positive) 5 6
Occult (HBcAb positive) 9 11
Hepatitis C virus (HCV) 85 100
HCVAb positive 7 8
HCV-RNA positive 3 4
HBsAg, Hepatitis B surface antigen; HBcAb, anti-hepatitis B core
antigen; HCVAb, anti-HCV.
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Given that HBV and HCV infections are frequent in the
Italian elderly population (Pendino et al, 2005), treatment
with highly immunosuppressive drugs such as alemtuzumab
may represent a major concern to clinicians. In the present
study, patients with both active and occult HBV and active
HCV infections received an adequate prophylactic treatment,
with a careful monitoring of hepatic function and viral load,
and they could be treated with low-dose alemtuzumab without
the occurrence of serious adverse events.
In conclusion, the present study confirms that alemtuzumab
given at low doses provides substantial clinical benefits to
relapsed/refractory CLL patients with acceptable toxicity, thus
proving the feasibility of this treatment approach in the
current clinical practice.
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